Multiple Myeloma · line 3 · Isatuximab + Carfilzomib + Dexamethasone (Isa-Kd), 28-day cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | standard |
| Linked regimen | REG-ISA-KD-MM-3L |
| ID | IND-MM-3L-ISA-KD |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-07 | pending_clinical_signoff |
| Diseases | DIS-MM |
| Sources | SRC-EHA-EMN-MM-2025 SRC-IKEMA-MOREAU-2021 SRC-NCCN-MM-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 3L for r/r MM after ≥2 prior lines (PI + IMiD) in carfilzomib-naive patients. Based on IKEMA (Moreau 2021, NEJM 385:427-440). NCCN Category 1. Near-equivalent to DKd (CANDOR) — both anti-CD38 + Kd combinations; choice is access-driven. No UA NSZU reimbursement for either isatuximab or carfilzomib.
Used By
Algorithms
ALGO-MM-3L- ALGO-MM-3L